In search of a vaccine for respiratory syncytial virus: The saga continues

Journal of Infectious Diseases

Volumn 191, Issue 7, 2005, Pages 1036-1039

  Englund, Janet ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; LIVE VACCINE; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

BRONCHIOLITIS; BUDGET; DRUG FATALITY; DRUG SCREENING; DRUG TOLERABILITY; ECONOMIC ASPECT; EDITORIAL; EPIDEMIC; HEALTH CARE ORGANIZATION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNIZATION; INFANT; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; SIDE EFFECT; TREATMENT FAILURE; VIRUS REPLICATION;

CLINICAL TRIALS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 15544388407     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427998     Document Type: Editorial

References (21)

1. Eberle J. A treatise on the diseases and physical education of children. Philadelphia: Lippincott, Grambo & Co., 1850:322-3.
2. Suara RO, Glezen WP. Contribution of respiratory viruses to the worldwide problem of pneumonia in young children. Semin Pediatr Infect Dis 1995; 6:121-7.
3. Glezen WP. Morbidity associated with the major respiratory viruses. Pediatr Ann 1990; 19: 535-8.
4. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13:371-84.
5. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-7.
6. Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principals and practice of infectious diseases. Philadelphia: Churchill Livingstone, 2000: 1782-801.
7. Adams JM. Primary virus pneumonitis with cytoplasmic inclusion bodies. JAMA 1941; 1156:925-33.
8. Chanock R, Rozman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCQ): I. Isolation, properties, and characterization. Am J Hyg 1957; 66:281-90.
9. Morris JA, Blount RE Jr, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 1956; 92: 544-9.
10. Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-21.
11. Hemming VG. Respiratory syncytial virus: a brief history. In: Weisman LE, Groothuis JR, eds. Contemporary diagnosis and management of respiratory syncytial virus. Newtown, PA: Handbooks in Health Care, 2000:7-23.
12. Kim HW, Canchola JG, Brandt BD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34.
13. Crowe JE Jr. Respiratory syncytial virus vaccine development. Vaccine 2001; 20(Suppl 1): S32-7.
14. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093-104 (in this issue).
15. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182: 1331-42.
16. Maggon K, Barik S. New drugs and treatment for respiratory syncytial virus. Rev Med Virol 2004; 14:149-68.
17. Nokes DJ, Okiro EA, Ngama M, et al. Respiratory syncytial virus epidemiology in a birth cohort from Kilifi District, Kenya: infection during the first year of life. J Infect Dis 2004; 190:1828-32.
18. Weber M, Mulholland E, Greenwood B. Respiratory syncytial virus infection in tropical and developing countries. Trop Med Int Health 1998; 3:268-80.
19. Michaud CM, Murray CJL, Bloom BR. Burden of disease: implications for future research. JAMA 2001; 285:535-9.
20. Englund JA. Prevention strategies for respiratory syncytial virus: passive and active immunization. J Pediatr 1999; 135(2 Pt 2):S38-44.
21. The Jordan Report 20th anniversary: accelerated development of vaccines 2002. National Institutes of Health, National Institute of Allergy and Infectious Diseases, and US Department of Health and Human Services, 2002:165-9. Available at: http://www.niaid .nih.gov/dmid/vaccines/jordan20/jordan20_ 2002.pdf. Accessed 1 December 2004.